NASDAQ:PGNY - Nasdaq - US74340E1038 - Common Stock - Currency: USD
PROGYNY INC
NASDAQ:PGNY (1/28/2025, 5:19:57 PM)
After market: 23.59 0 (0%)23.59
+0.64 (+2.79%)
The current stock price of PGNY is 23.59 USD. In the past month the price increased by 60.37%. In the past year, price decreased by -39.65%.
Provides expecting parents with a concierge-level service model that delivers expert guidance, navigation and support for parental leave planning
Provides expecting parents with a concierge-level service model that delivers expert guidance, navigation and support for parental leave planning...
Sonos, Moderna, and Shake Shack are all staring at some near-term headwinds – can they work through them?
NEW YORK, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building and women’s health benefits...
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
UNH | UNITEDHEALTH GROUP INC | 19.43 | 499.23B | ||
ELV | ELEVANCE HEALTH INC | 12.3 | 94.02B | ||
HUM | HUMANA INC | 16.62 | 36.50B | ||
CNC | CENTENE CORP | 9.59 | 32.68B | ||
MOH | MOLINA HEALTHCARE INC | 13.99 | 17.58B | ||
HQY | HEALTHEQUITY INC | 35.08 | 9.33B | ||
ALHC | ALIGNMENT HEALTHCARE INC | N/A | 2.92B | ||
CLOV | CLOVER HEALTH INVESTMENTS CO | N/A | 2.30B | ||
NEUE | NEUEHEALTH INC | 5.57 | 60.93M |
Progyny, Inc. is a fertility benefits management company. The company is headquartered in New York City, New York and currently employs 563 full-time employees. The company went IPO on 2019-10-25. The firm specializes in fertility and family building benefits solutions in the United States. The Company’s clients include various employers across an array of industries. The company has contracts to provide coverage to approximately 6.4 million employees and their partners (known as members). The firm provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. The company provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.
PROGYNY INC
1359 Broadway
New York City NEW YORK 10018 US
CEO: David Schlanger
Employees: 563
Company Website: https://www.progyny.com/
Investor Relations: https://investors.progyny.com/
Phone: 12128883124
The current stock price of PGNY is 23.59 USD.
The exchange symbol of PROGYNY INC is PGNY and it is listed on the Nasdaq exchange.
PGNY stock is listed on the Nasdaq exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for PGNY, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of PGNY.
PGNY does not pay a dividend.
The PE ratio for PGNY is 40.67. This is based on the reported non-GAAP earnings per share of 0.58 and the current share price of 23.59 USD.
The outstanding short interest for PGNY is 16.18% of its float.
ChartMill assigns a technical rating of 7 / 10 to PGNY. When comparing the yearly performance of all stocks, PGNY turns out to be only a medium performer in the overall market: it outperformed 63.86% of all stocks.
ChartMill assigns a fundamental rating of 7 / 10 to PGNY. PGNY gets an excellent profitability rating and is at the same time showing great financial health properties.
Over the last trailing twelve months PGNY reported a non-GAAP Earnings per Share(EPS) of 0.58. The EPS increased by 11.54% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 5.03% | ||
ROA | 8.68% | ||
ROE | 13.17% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 76% to PGNY. The Buy consensus is the average rating of analysts ratings from 16 analysts.
For the next year, analysts expect an EPS growth of -9.78% and a revenue growth 4.76% for PGNY